Strategic Blueprint’s Abiomed Inc ABMD Stock Holding History

Strategic Blueprint’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-69	Closed	-$12K	–	449
2019 Q3	$12K	Buy	+69	New	+$14.9K	0.01%	287

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Strategic Blueprint's ABMD Position: Q4 2019 in Review

Strategic Blueprint sold out of Abiomed Inc (ABMD) in Q4 2019, closing a stake of 69 shares — an estimated $12K sold.

Strategic Blueprint first reported a position in ABMD in Q3 2019 and held it in 1 quarter. The position peaked at $12K in Q3 2019. 465 funds tracked by Wall St. Rank hold ABMD as of Q4 2019.

Strategic Blueprint reported no remaining Abiomed Inc position as of Q4 2019 after selling out during the quarter.
Strategic Blueprint sold 69 Abiomed Inc shares in Q4 2019, an estimated $12K.
Strategic Blueprint first reported a position in Abiomed Inc in Q3 2019 and held it in 1 quarter.
Strategic Blueprint's Abiomed Inc position peaked at $12K in Q3 2019.
465 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2019.

Based on Strategic Blueprint's 13F filing for Q4 2019, filed 10 Jan 2020.